推荐产品
化驗
≥98% (TLC)
形狀
powder
顏色
white to off-white
mp
191-192 °C (lit.)
溶解度
DMSO: 50 mg/mL, clear
起源
Johnson & Johnson
儲存溫度
room temp
SMILES 字串
Clc1ccc2OC(=O)Nc2c1
InChI
1S/C7H4ClNO2/c8-4-1-2-6-5(3-4)9-7(10)11-6/h1-3H,(H,9,10)
InChI 密鑰
TZFWDZFKRBELIQ-UHFFFAOYSA-N
基因資訊
human ... KCNN4(3783)
正在寻找类似产品? 访问 产品对比指南
應用
Chlorzoxazone may be used:
- as a calcium-activated potassium (KCa) channel activator in patch-clamp electrophysiology to test its effect on dendritic hyperexcitability
- as a substrate for cytochrome P450 2E1 (CYP2E1) enzyme in cultured human hepatocytes
- as a benzimidazolone compound to test its effect on epithelial sodium (Na+) transport
生化／生理作用
Chlorzoxazone inhibits the multisynaptic reflex arcs primarily in the spinal cord and brain subcortical areas. It is an activator of calcium activated potassium channels and may contribute to the aortic artery relaxation in mice. Chlorzoxazone also activates the calcium-activated potassium (KCa) channel and small conductance calcium-activated potassium channels (SK). It is metabolized by cytochrome P450 2E1 (CYP2E1) and serves as a probe for monitoring this enzyme function.
Chlorzoxazone is a skeletal muscle relaxant.
特點和優勢
This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the Potassium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
訊號詞
Warning
危險分類
Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
標靶器官
Respiratory system
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
個人防護裝備
dust mask type N95 (US), Eyeshields, Gloves
其他客户在看
Cyrus Ghobadi et al.
Clinical pharmacokinetics, 50(12), 809-822 (2011-11-18)
The maintenance dose of a drug is dependent on drug clearance, and thus any biochemical and physiological changes in obesity that affect parameters such as cardiac output, renal function, expression of drug-metabolizing enzymes and protein binding may result in altered
F Woodward Hopf et al.
Biological psychiatry, 69(7), 618-624 (2011-01-05)
Alcoholism imposes a tremendous social and economic burden. There are relatively few pharmacological treatments for alcoholism, with only moderate efficacy, and there is considerable interest in identifying additional therapeutic options. Alcohol exposure alters SK-type potassium channel (SK) function in limbic
Yong-Long Han et al.
Journal of ethnopharmacology, 139(1), 104-109 (2011-11-15)
Herba Erigerontis injection (HEI), one of the most popular herbal prescription in China, is made from the aqueous extracts of Erigeron breviscapus whole plant. Now HEI is widely used for the treatment of cardiovascular diseases and cerebrovascular diseases such as
Karina Alviña et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 30(21), 7249-7257 (2010-05-28)
Episodic ataxia type-2 (EA2) is an inherited movement disorder caused by mutations in the gene encoding the Ca(v)2.1alpha1 subunit of the P/Q-type voltage-gated calcium channel that result in an overall reduction in the P/Q-type calcium current. A consequence of these
Karina Alviña et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 30(21), 7258-7268 (2010-05-28)
Episodic ataxia type 2 (EA2) is a hereditary cerebellar ataxia associated with mutations in the P/Q-type voltage-gated calcium (Ca(2+)) channels. Therapeutic approaches for treatment of EA2 are very limited. Presently, the potassium (K(+)) channel blocker 4-aminopyridine (4-AP) constitutes the most
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门